| |
|
Product Name:
|
Monoclonal Anti-Influenza Virus H9 Hemagglutinin (HA) Protein (1073-9), A/Hong Kong/1073/1999 (H9N2) (ascites, Mouse)
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
St. Jude Children’s Research Hospital (CEIRS)
|
|
Material Provided:
|
Each vial of NR-9488 contains lyophilized (0.2 mL containing 0.02% sodium azide and 0.01% gentamycin) mouse ascites fluid.
|
|
Packing/Storage:
|
NR-9488 was packaged in glass serum vials with an aluminum crimp seal. The product is provided frozen and should be stored at -20°C to -40°C immediately upon arrival. Storage at warmer temperatures is not recommended due to a low bioburden. At colder temperatures, the rubber stopper may become brittle and compromise the seal. NR-9488 should be reconstituted with 0.2 mL of sterile distilled water. Reconstituted material should be stored at -20°C to -40°C. Reconstituted material may be thawed at room temperature and should be re-frozen.
|
|
Functional Activity:
|
NR-9488 is specific for the H9 HA subtype of the influenza A virus as determined in standard hemagglutination inhibition (HI) assays. NR-9488 also demonstrates reactivity within the H9 HA subtype. HI titers with 20 different influenza strains of the H9 HA subtype representing Eurasian and North American lineages, as well as H9 HA viruses from other geographic areas, are shown on the Certificate of Analysis. No reactivity was observed with several viruses of North American lineage.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Xu, K. M., et al. “Evolution and Molecular Epidemiology of H9N2 Influenza A Viruses from Quail in Southern China, 2000 to 2005.” J. Virol. 81 (2007): 2635-2645. PubMed: 17192315.
2. Butt, K. M., et al. “Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003.” J. Clin. Microbiol. 43 (2005): 5760-5767. PubMed: 16272514.
3. Choi, Y. K., et al. “Continuing Evolution of H9N2 Influenza Viruses in Southeastern China.” J. Virol. 78 (2004): 8609-8614. PubMed: 15280470.
4. Lin, Y. P., et al. “Avian-to-Human Transmission of H9N2 Subtype Influenza A Viruses: Relationship between H9N2 and H5N1 Human Isolates.” Proc. Natl. Acad. Sci. USA 97 (2000): 9654-9658. PubMed: 10920197. GenPept: CAB95856.
5. Saito, T., W. Lim. and M. Tashiro. “Attenuation of a Human H9N2 Influenza Virus in Mammalian Host by Reassortment with an Avian Influenza Virus.” Arch. Virol. 149 (2004): 1397-1407. PubMed: 15221539.
6. Stephenson, I., et al. “Safety and Antigenicity of Whole Virus and Subunit Influenza A/Hong Kong/1073/99 (H9N2) Vaccine in Healthy Adults: Phase I Randomised Trial.” Lancet 362 (2003): 1959-1966. PubMed: 14683655.
7. Pushko, P., et al. “Influenza Virus-Like Particles Comprised of the HA, NA, and M1 Proteins of H9N2 Influenza Virus Induce Protective Immune Responses in BALB/c Mice.” Vaccine 23 (2005): 5751-5759. PubMed: 16143432.
8. Pushko, P., et al. “Evaluation of Influenza Virus-Like Particles and Novasome Adjuvant as Candidate Vaccine for Avian Influenza.” Vaccine 25 (2007): 4283-4290. PubMed: 17403562.
9. Saito, T., et al. “Characterization of a Human H9N2 Influenza Virus Isolated in Hong Kong.” Vaccine 20 (2001): 125-133. PubMed: 11567756.
10. Guan, Y., et al. “H9N2 Influenza Viruses Possessing H5N1-Like Internal Genomes Continue to Circulate in Poultry in Southeastern China.” J. Virol. 74 (2000): 9372- 9380. PubMed: 11000205.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza Virus H9 Hemagglutinin (HA) Protein (1073-9), A/Hong Kong/1073/1999 (H9N2), (ascites, Mouse), NR-9488."
|
|
Biosafety Level:
|
1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|